8-K: Xencor Regains Full Rights to Plamotamab After Janssen Terminates Agreement

Xencor will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen Biotech terminates their collaboration agreement.

Summary

• Xencor has regained exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen Biotech terminated their collaboration agreement.
• The collaboration, initiated in 2021, involved the development and commercialization of plamotamab and other B-cell targeting bispecific antibodies.
• Xencor completed a Phase 1 study of plamotamab in late 2023, and the drug is now considered Phase 2 ready.
• Janssen will retain rights to develop and commercialize other B-cell targeting CD28 bispecific antibodies, including JNJ-9401 and JNJ-1493.
• Xencor is eligible for milestone payments and royalties on Janssen's CD28 bispecific antibodies, with potential for higher royalties if they opt-in to fund a portion of development costs and detailing efforts.

Sentiment

Score: 6

Explanation: The news is mixed. While regaining full rights to plamotamab is a positive, it also means Xencor will bear the full development costs. The potential for future royalties from Janssen is a positive, but the termination of the plamotamab agreement by Janssen is a concern.

Positives

• Xencor now has full control over the future development and commercialization of plamotamab.
• Plamotamab is Phase 2 ready, indicating it has already shown some promise in clinical trials.
• Xencor retains the potential for milestone payments and royalties from Janssen's other bispecific antibody programs.
• The company has the option to increase its royalty rates by funding a portion of development costs and detailing efforts for Janssen's programs.

Negatives

• Janssen's termination of the plamotamab agreement could indicate a lack of confidence in the drug's potential.
• Xencor will now bear the full financial burden of developing plamotamab, which could be significant.
• The company will need to allocate resources to evaluate the potential of plamotamab and determine its future development path.

Risks

• The future development of plamotamab is subject to the risks associated with drug development, including clinical trial failures and regulatory hurdles.
• Xencor may not be able to successfully commercialize plamotamab on its own.
• The company's financial resources may be strained by the need to fund the development of plamotamab.
• There is no guarantee that plamotamab will be successful in addressing unmet medical needs.

Future Outlook

Xencor will review the potential of plamotamab for addressing unmet medical needs and will likely pursue further development of the drug. The company will also continue to receive potential milestone payments and royalties from Janssen's other bispecific antibody programs.

Management Comments

• Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, stated that they will review plamotamab's potential for addressing unmet medical needs.

Industry Context

The termination of the agreement by Janssen highlights the risks and uncertainties inherent in pharmaceutical collaborations. It also underscores the value of bispecific antibody technology, as both Xencor and Janssen continue to pursue development in this area. The competitive landscape for cancer therapies is intense, and companies are constantly seeking new and innovative approaches.

Comparison to Industry Standards

• The development of bispecific antibodies is a growing trend in the pharmaceutical industry, with companies like Amgen (Blincyto) and Roche (Hemlibra) having already achieved commercial success with this technology.
• Xencor's plamotamab, targeting CD20 and CD3, is similar to other bispecific antibodies in development for B-cell malignancies, such as Roche's glofitamab.
• The royalty rates mentioned in the document are within the typical range for pharmaceutical licensing agreements, with higher rates for products that are co-developed or co-marketed.
• The decision by Janssen to terminate the agreement for plamotamab while continuing with other bispecific programs is not uncommon, as companies often prioritize their pipelines based on clinical data and strategic considerations.

Stakeholder Impact

• Shareholders may react positively to Xencor regaining full rights to plamotamab, but also negatively to the increased development costs.
• Employees may be impacted by the shift in focus and resources towards plamotamab.
• Patients with B-cell malignancies may benefit from the potential development of plamotamab as a new treatment option.

Next Steps

• Xencor will review the potential of plamotamab for addressing unmet medical needs.
• Xencor will likely make decisions regarding the future development path for plamotamab.
• Xencor will continue to monitor the progress of Janssen's CD28 bispecific antibody programs.

Key Dates

Keywords

plamotamab, Xencor, Janssen, bispecific antibody, CD20, CD3, T-cell engager, hematologic cancers, clinical development, royalty, milestone payments